



TuBerculosis Vaccine Initiative

Draft Programme

Annual TBVI Meeting

Innovating and Delivering TB Vaccines and Biomarkers

18 – 20 January 2022

Hotel Eurotel Victoria
Les Diablerets
Switzerland



TuBerculosis Vaccine Initiative

Tuesday 18 January

12.30 – 14.00 *Lunch- Restaurant Eurotel*

Maison des Congres

15:00 – 15:20 TB vaccine R&D Portfolio - towards next generation vaccines (*speaker tbc*)

15.20 – 18.00 **Session 1. Mechanisms of immune protection: vaccination strategies to accelerate and maintain local immune protection. (Chairs Andrea Cooper / Rasmus Mortensen)**

All speakers session 1 t.b.c.

- | | | |
|---------------|--|---------------------------------|
| 15.20 – 15.30 | Introduction/overview | - Andrea Cooper, United Kingdom |
| 15.30 – 16.00 | Local immune responses in the lung | - Daniel Barber, United States |
| 16.00 – 16.15 | Maturation of iBALT can be mediated by vaccination and serve as backdoor for T cells to the Mycobacterium tuberculosis (Mtb) infected lung | - Thomas Lindenstrom, Denmark |
| 16.15 – 16.30 | Pulmonary BCG induces lung-resident macrophage activation and confers long-term protection against tuberculosis. | - <i>speaker tbc</i> |

16.30 - 17.00 *Coffee/Tea – Maison des Congres*

17.00 – 18.00 **Session 1. Mechanisms of immune protection: vaccination strategies to accelerate and maintain local immune protection**

- | | | |
|---------------|---|-----------------------------|
| 17.00 – 17.30 | Division of labor in the lung during pulmonary infection | - Carolyn King, Switzerland |
| 17.30 – 17.45 | Intravital imaging | - Emma Lefrancais, France |
| 17.45 – 18.00 | A protective role for lung Interstitial CD4+ T cells
Lessons from HIV/Mtb co-infection | - Bjorn Corleis, Germany |

18.30 - 19.30 *Reception – Bar/Entrance Hall Eurotel*

19.30 *Dinner - Restaurant Eurotel*



TuBerculosis Vaccine Initiative

Wednesday 19 January 2022

Maison des Congres

- 09.00-10.15 **Session 2. Towards next generation TB vaccines: innovation of the pipeline through new delivery platforms and novel vaccination routes (Chairs: Mei Mei Ho/Camille Locht).**
- 09.00- 09.10 Update since the end of TBVAC2020 – Mei Mei Ho, United Kingdom
Camille Locht, France.
- 09.10- 09.30 Alternative delivery routes for (re)vaccination using live TB vaccines towards enhanced efficacy Frank Verreck, Netherlands
- 09.30- 09.50 mRNA vaccines for TB *speaker tbc*
- 09.50 -10.10 Nanoparticle-fusion proteins and mucosal vaccination Rajko Reljic, United Kindom.
- 10.10 - 10.40 *Coffee/Tea – Maison des Congres*
- 10.40-12.00 **Session 2. Towards next generation TB vaccines: innovation of the pipeline through new delivery platforms and novel vaccination routes (Chairs: Mei Mei Ho/Camille Locht).**
- 10.40-11.00 Lentiviral vectors expressing Mtb antigens Laleh Majlessi, France.
- 11.00-11.20 A new Mtb specific protein-adjuvant vaccine that bypass T-cell-imprint from BCG and improve protection Rasmus Mortensen, Denmark
- 11.20-11.40 Recombinant BCG:ESX vaccines Roland Brosch, France.
- 11.40-12.00 CysVAC TB vaccines Warwick Britton, Australia.
- 12.00 - 13.00 *Lunch - Restaurant Eurotel*
- 13.00 –14.30 **Session 3. Correlates of protection: innovating and validating the pipeline (Chairs: Hazel Dockrell/Tom Ottenhoff)**
- 13.00 -13.25 Major achievements TBVAC2020 WP5 Simone Joosten, Netherlands.
- 13.25- 14.00 Correlates of protection and clinical TB vaccine development Tom Scriba, South Africa.
- 14.00-14.25 What can we learn from TB BM in NHP? A review Sally Sharpe, United Kingdom (*tbc*)
- 14.25 – 14.50 *Coffee/Tea – Maison des Congres*



TuBerculosis Vaccine Initiative

Wednesday 19 January 2022

Maison des Congres

14.50 – 16.05 **Session 3. Correlates of protection: innovating and validating the pipeline**
(Chairs: Hazel Dockrell/Tom Ottenhoff)

- | | | |
|-------------|--|-------------------------------|
| 14.50-15.15 | High dimensional analysis of pulmonary responses in TB | Erin McCaffrey, USA. |
| 15.15-15.40 | The macrophage problem: What is it and how can we resolve it. | David Russell, USA. |
| 15.40-16.05 | Host transcriptomic biomarkers through TB treatment with Diabetes comorbidity. | Jackie Cliff, United Kingdom. |

16.10 – 16.20 *Photo whole group outside in front of the Maison des Congres*

16.30 – 18.15 TBVI Steering Committee Meeting (for SC members only)

19.30 *Dinner - Restaurant Eurotel*



TuBerculosis Vaccine Initiative

Thursday 20 January 2022

Maison des Congres

09:00 - 12:00 **Session 4. - Experimental Medicine and Clinical Trials**
(Chairs: HelenMcShane, Bernard Fritzell)

09.00 – 09.20	Introduction/overview	- Helen McShane, United Kingdom.
09.20 – 09.40	Adaptive clinical trials in sub-Saharan Africa	- Mark Hatherill, South Africa.
09.40 – 10.00	BCG against COVID-19	- Nigel Curtis, Australia.
10.00 – 10.20	Lessons from COVID-19	- speaker tbc

10.20 – 10.50 *Coffee/Tea – Maison des Congres*

10.50 – 12.00 **Session 4. - Experimental Medicine and Clinical Trials**
(Chairs: HelenMcShane, Bernard Fritzell)

10.50 – 11.10 Controlled human challenge studies for TB vaccines - Brian Robertson, United Kingdom

Short talks ongoing trials in TBVAC2020/EDCTP Projects

11.10 – 11.20	ChAdOx1 85A Aerosol/MVA 85A IM	- Francois Spertini, Switzerland (<i>tbc</i>)
11.20 – 11.30	MTBVAC coming to Phase 3 Trial	- Ingrid Murillo, Spain.
11.30 – 11.40	VPM1002	- Leander Grode, Germany.
11.40 – 11.50	H56/IC31	- Alvaro Borges, Denmark.
11.50 – 12.00	RUTI	- Pere Joan Cardona, Spain.

12.15 – 14.00 *Buffet lunch - Restaurant Eurotel*

Side meetings